SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
ABT: Bull or Bear?
Full FDA Calendar of Decision Dates
ABT
|
|
|
-4.23%
in
11 days
 The accompanying table presents a full FDA calendar of decision dates updated through today, which I will maintain at the bottom of my blog in place of the previous Global Carbon Trading Index. Click on the calendar image above or on my blog to view or download the PDF version of the FDA calendar, which I will also maintain at: www.geocities.com/mikehavrx/fdac.pdf . Several key decisions are pending through the end of this month for the group of 14 big pharma companies I outlined yesterday, including Eli Lilly (L ...
|
Pfizer is a Big Pharma Buy
ABT
|
|
|
+0.00%
in
13 hours
(closed on 09/25/08)
 The accompanying table presents an overview of big pharma companies, presented in descending order by market cap. My favorite play in the space remains to be Pfizer (PFE), which I have written about previously and finally bought shares today at $17.90 with a dividend yield exceeding 7%. Despite growth concerns and looming generic competition for Lipitor in late 2011, I bought shares of Pfizer today as a value pick and turnaround play which operates in a defensive sector with a strong balance sheet. Also, the Company is aggressive ...
|
The Long Case for Abbott Laboratories
ABT
-0.98%
in
74 days
Abbott Laboratories (ABT) is a good company for dividend-seekers and long-term-growth investors, currently trading at a decent valuation. Company/Stock TypeLarge, mature growth company. Business = Diversified healthcare, including drugs, medical devices, and nutritional products.
|
Healthy Growth for Abbott Labs
ABT
|
|
|
+2.28%
in
67 days
(closed on 09/24/08)
Abbott Labs (NYSE: ABT) posted better than expected earnings and sales growth and raised its guidance this morning, reflected in the above 1-year stock chart which shows the Company has outperformed the S&P 500 index by over 30% and the Healthcare Sector SPDR exchange-traded fund (XLV) by over 20%. Results included the following:
-global sales growth of 14.8% to $7.3 billion (B)
-pharmaceutical sales ($4.1B) growth of 16.7% led by Humira (a biological agent for autoimmune diseases such as rheumatoid arthritis), which experienced a 48% growth in sales for 1H08 at $1 ...
|
Abbott Proves Successful in a Very Tough Market
ABT
-1.23%
in
81 days
While many earnings reports these days are disconcerting to investors as fuel prices weigh on the economy, we think it is important to note those companies that are beating expectations.  Beating estimates amidst tough circumstances is a sign of solid management, which is always a positive for investors. Abbott Laboratories (ABT) announced an impressive second quarter earnings increase of 34%, which surprised Wall Street with strong growth for its blockbuster arthritis drug Humira. It produced sales of over $1 billion, up 48 percent from last year. Also impressive were the double digit gains ...
|
Turnaround time for drug stocks? 10 top picks
ABT
+0.64%
in
125 days
Filed under: Pfizer (PFE), Newsletters, Johnson and Johnson (JNJ), Abbott Laboratories (ABT), Bristol-Myers Squibb (BMY), Merck and Co (MRK), Lilly (Eli) (LLY), Stocks to Buy  "You can invest for all the right reasons and still get the wrong result," notes long-standing turnaround stock expert George Putnam, referring to the poor performance of the pharmaceutical sector in recent years.
Here, in his industry-leading The Turnaround Letter, he offers a fascinating review of 10 leading drug stocks which he now believes offer a combination of growth potential at "pretty cheap" valuations. Here is ...
|
Turnaround time for pharmaceuticals?
ABT
|
|
|
+0.36%
in
129 days
 "You can invest for all the right reasons and still get the wrong result," says George Putnam, referring to the poor performance of the pharmaceutical sector in recent years.
Here, in his industry-leading The Turnaround Letter, he offers a fascinating review of 10 leading drug stocks which he now believes offer a combination of growth potential at "pretty cheap" valuations. "In 2000 and 2001, when the Internet boom was becoming a bust, many smart investors turned away from technology stocks and put their money into drug stocks. How could you go wrong with the big pharmaceutical companies? "De ...
|
Merck's Rejection Good News for Abbott, But Other Issues Remain
ABT
-4.50%
in
157 days
4/29 - "The non-approval of Cordaptive is good news for ABT’s niacin franchise. Since our forecasts did have Cordaptive getting approved we are raising our estimates for ABT’s Niaspan and Simcor...While we had forecast most of the growth of Cordaptive coming from new patients (that had troubles with niacin flushing), we did assume some share erosion for Niaspan in 2008 and Simcor in 2009. We are now expecting Niaspan to grow at a 12% 2008-12 CAGR (up from 7%) and Simcor to grow 18% up from 13%. These changes up our 2009 and 2010 estimates by $0.04 each."
"We rate the shares of Abbott Labor...
|
Merck News Makes Abbott Labs Look Appealing
ABT
+4.50%
in
157 days
4/29 - "Abbott Laboratories (NYSE: ABT) shares are trading higher after the Food and Drug Administration denied regulatory approval for Merck & Co.'s (NYSE: MRK) cholesterol drug Cordaptive. The Merck drug would have directly competed with ABT's own cholesterol drug. If you think that the stock won't fall by too much in the coming months, then now could be a good time to look at a bullish hedged trade on ABT."
"For a bullish hedged play on this stock, I would consider a June bull-put credit spread below the $50 range. A bull-put credit spread is an options position that combines the purcha...
|
Dividends Are Not Signalling Recession
ABT
+1.48%
in
24 days
(closed on 03/26/08)
 If the US economy is falling into recession, you could not discern it from the dividend actions of major US companies over the last two weeks. As you know, one of our theories on dividends is that since dividends are decided by a company's board of directors, they speak as much about the future as the past . This is because no board wants to set a dividend policy that will lead to a cut in the dividend in the future. If our theory is correct, business is not as bad as the headlines would have us believe. According to the chart at the right, dividend growth remains strong. (Click to enlar
|
Tough Questions, Controversial Answers
ABT
+4.39%
in
194 days
The air is thick with concerns, worries, and just plain confusion regarding the economy and stocks. Over the next few editions, I will try to answer the most prevalent and important questions our portfolio managers are receiving.
Question: Recession, yes or no, and if yes, how deep and how long.
Answer: I really believe this is the wrong question for 95% of investors to be asking. The reason is that most of the stocks in the major indices derive nearly 50% of their earnings outside the US and whatever happens here will be buffered by what happens around the world. Here is an import point to p...
|
Vytorin Pain May Be Abbott's Gain
ABT
+1.97%
in
189 days
3/31 - "What’s bad for Merck and Schering-Plough may be good for Abbott Laboratories. Yesterday’s downbeat discussion about Vytorin at a meeting of caridologists may lead doctors to look farther for alternative cholesterol treatments when statins aren’t getting the job done. The search may lead them to Abbott.
Abbott markets niacin-based drugs called Niaspan and SimCor (a combination of Niaspan and generic Zocor) as well as a fibrate drug called TriCor. Both niacins and fibrates are classes of cholesterol medicines that the New England Journal of Medicine calls suitable for use when first-...
|
Bullish on ABT ...
ABT
|
|
|
+3.37%
in
474 days
Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products worldwide. It operates in four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. The Pharmaceutical Products segment offers adult and pediatric pharmaceuticals for the treatment of dyslipidemia, cholesterol, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, hypothyroidism, obesity, HIV infection, epilepsy and bipolar disorder, migraines, hyperparathyroidism, endometriosis and central precocious puberty, anemia, duodenal ...
|
People Bullish on ABT
People Bearish on ABT
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Be the first to start a discussion and earn 2 points.
More Resources
|
